VF
CADL icon

Virtu Financial’s Candel Therapeutics CADL Stock Holding History

Virtu Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,832
Closed -$152K – 1688
2025
Q4 		$152K Buy
+26,832
New +$144K 0.01% 1107
2024
Q3 		– Sell
-22,639
Closed -$140K – 1418
2024
Q2 		$140K Buy
+22,639
New +$170K 0.01% 783

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's CADL Position: Q1 2026 in Review

Virtu Financial sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 26,832 shares — an estimated $152K sold.

Virtu Financial first reported a position in CADL in Q2 2024 and held it in 2 quarters. The position peaked at $152K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Virtu Financial reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 26,832 Candel Therapeutics shares in Q1 2026, an estimated $152K.
  • Virtu Financial first reported a position in Candel Therapeutics in Q2 2024 and held it in 2 quarters.
  • Virtu Financial's Candel Therapeutics position peaked at $152K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.